| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Including dementia with Lewy bodies (DLB), Parkinson’s disease (PD), and multiple system atrophy (MSA), synucleinopathies are a diverse group of conditions characterized by the aberrant misfolding of the α-synuclein protein in neurons. Because these conditions are associated with faster cognitive decline, more rapid disease progression, poorer prognosis, and treatment contraindications compared to classic Alzheimer’s disease and other neurodegenerative conditions, identifying synuclein pathology is imperative to provide patients with the best possible care. Evaluating for the presence of misfolded α-synuclein in cerebrospinal fluid (CSF) can equip physicians with precise answers to diagnose, stratify, and manage their patients.1
Synucleinopathy test menu
The SAAmplify™–αSYN is a first-in-class seed amplification assay for the detection of misfolded α-synuclein in cerebrospinal fluid. Intended for patients with clinically uncertain cognitive decline or Parkinsonian syndromes, results can help diagnose synucleinopathies, such as PD, DLB, Alzheimer's disease with Lewy body pathology (AD-LB), and MSA. The SAAmplify–αSYN assay is the only seed amplification assay commercially available to detect synucleinopathies in CSF and can accurately identify α-syn pathology even before definitive symptoms appear.
Key testing
Advantages
Additional information
Dementia with Lewy bodies (DLB) is the most common type of dementia after Alzheimer’s disease (AD) dementia. Unlike classic AD, which impacts memory, language, and behavior, DLB affects executive function, speed of cognition, movement, mood, and memory. Often, an early presenting symptom of DLB is hallucinations. Because DLB progresses more quickly than classic AD, has a poorer prognosis, and responds adversely to certain medications often used to treat psychosis and agitation (e.g., Ativan and Haldol), early, accurate diagnosis is critical. Diagnostic clarity not only enables accurate prognosis, it also allows for the selection of safer medication alternatives and time to plan for supportive care needed by patients to maintain and enhance their quality of life.